{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:40:45Z","timestamp":1770741645505,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00415-020-10257-z","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T15:03:00Z","timestamp":1602342180000},"page":"4549-4562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-697X","authenticated-orcid":false,"given":"Sasitorn","family":"Siritho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0428-973X","authenticated-orcid":false,"given":"Tanawin","family":"Nopsopon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3818-9761","authenticated-orcid":false,"given":"Krit","family":"Pongpirul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"10257_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","volume":"3","author":"K Fujihara","year":"2012","unstructured":"Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, Lassmann H (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3:58\u201373","journal-title":"Clin Exp Neuroimmunol"},{"key":"10257_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","volume":"126","author":"J Ratelade","year":"2013","unstructured":"Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS (2013) Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelaination in a mouse model of neuromyelitis optica. Acta Neuropathol 126:699\u2013709","journal-title":"Acta Neuropathol"},{"key":"10257_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","volume":"120","author":"R Sharma","year":"2010","unstructured":"Sharma R, Fischer M, Bauer J, Felts P, Smith K, Misu T (2010) Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 120:223\u2013236","journal-title":"Acta Neuropathol"},{"key":"10257_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2004.07.003","volume":"225","author":"T Fukazawa","year":"2004","unstructured":"Fukazawa T, Kikuchi S, Niino M et al (2004) Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders. J Neurol Sci 225:71\u201378","journal-title":"J Neurol Sci"},{"key":"10257_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"D Wingerchuk","year":"2007","unstructured":"Wingerchuk D, Lennon V, Lucchinetti C, Pittock S, Weinshenker B (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"10257_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H (2017) Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 88:137\u2013145","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10257_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"B Weinshenker","year":"1999","unstructured":"Weinshenker B, O'Brien PC, Petterson T et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878\u2013886","journal-title":"Ann Neurol"},{"key":"10257_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","volume":"13","author":"S Aungsumart","year":"2017","unstructured":"Aungsumart S, Apiwattanakul M (2017) Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature. Mult Scler Relat Disord 13:93\u201397","journal-title":"Mult Scler Relat Disord"},{"key":"10257_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1352458508100837","volume":"15","author":"M Bonnan","year":"2009","unstructured":"Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15:487\u2013492","journal-title":"Mult Scler"},{"key":"10257_CR10","first-page":"735486","volume":"2012","author":"W Kim","year":"2012","unstructured":"Kim W, Kim S, Huh S, Kim H (2012) Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012:735486","journal-title":"Mult Scler Int"},{"key":"10257_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2015","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2015) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206\u2013216","journal-title":"Ann Neurol"},{"key":"10257_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1177\/1352458512471875","volume":"19","author":"Y Lim","year":"2013","unstructured":"Lim Y, Pyun S, Kang B, Kim J, Kim K (2013) Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 19:1216\u20131218","journal-title":"Mult Scler"},{"key":"10257_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130:858\u2013862","journal-title":"Arch Ophthalmol"},{"key":"10257_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.msard.2018.01.010","volume":"20","author":"T Srisupa-Olan","year":"2018","unstructured":"Srisupa-Olan T, Siritho S, Kittisares K, Jitprapaikulsan J, Sathukitchai C, Prayoonwiwat N (2018) Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 20:115\u2013121","journal-title":"Mult Scler Relat Disord"},{"key":"10257_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1352458506071174","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple Sclerosis 13:128\u2013132","journal-title":"Multiple Sclerosis"},{"key":"10257_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher 34:171\u2013354","journal-title":"J Clin Apher"},{"key":"10257_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","volume":"164","author":"H Reeves","year":"2014","unstructured":"Reeves H, Winters J (2014) The mechanisms of action of plasma exchange. Br J Haematol 164:342\u2013351","journal-title":"Br J Haematol"},{"key":"10257_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1941874412466873","volume":"3","author":"MR Rahmlow","year":"2013","unstructured":"Rahmlow MR, Kantarci O (2013) Fulminant demyelinating diseases. Neurohospitalist 3:81\u201391","journal-title":"Neurohospitalist"},{"key":"10257_CR19","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"D Wingerchuk","year":"2006","unstructured":"Wingerchuk D, Lennon V, Pittock S, Lucchinetti C, Weinshenker B (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"10257_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"D Wingerchuk","year":"2015","unstructured":"Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"10257_CR21","doi-asserted-by":"publisher","first-page":"i4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:i4898","journal-title":"BMJ"},{"key":"10257_CR22","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"J Sterne","year":"2016","unstructured":"Sterne J, Hern\u00e1n M, Reeves B et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"10257_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"J Kurtzke","year":"1983","unstructured":"Kurtzke J (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"10257_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M (2016) Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 22:185\u2013192","journal-title":"Mult Scler"},{"key":"10257_CR25","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s10792-019-01090-z","volume":"39","author":"W Song","year":"2019","unstructured":"Song W, Qu Y, Huang X (2019) Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol 39:2477\u20132483","journal-title":"Int Ophthalmol"},{"key":"10257_CR26","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.msard.2019.101506","volume":"38","author":"T Songthammawat","year":"2019","unstructured":"Songthammawat T, Srisupa-Olan T, Siritho S, Kittisares K, Jitprapaikulsan J, Sathukitchai C (2019) A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous IVMP and PLEX. Mult Scler Relat Disord 38:101506","journal-title":"Mult Scler Relat Disord"},{"key":"10257_CR27","first-page":"787630","volume":"2012","author":"M Bonnan","year":"2012","unstructured":"Bonnan M, Cabre P (2012) Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012:787630","journal-title":"Mult Scler Int"},{"key":"10257_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1586\/ern.09.81","volume":"9","author":"A Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der A, Linker R, Gold R (2009) Plasmapheresis for neurological disorders. Expert Rev Neurother 9:1331\u20131339","journal-title":"Expert Rev Neurother"},{"key":"10257_CR29","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","volume":"373","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905\u20131917","journal-title":"Lancet"},{"key":"10257_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell B, Vincent A, Verkman A, Papadopoulos M (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349\u2013361","journal-title":"Brain"},{"key":"10257_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","volume":"9","author":"S Kim","year":"2013","unstructured":"Kim S, Kim W, Huh S, Lee K, Jung I, Kim H (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 9:36\u201342","journal-title":"J Clin Neurol"},{"key":"10257_CR32","doi-asserted-by":"publisher","first-page":"146219","DOI":"10.1155\/2013\/146219","volume":"2013","author":"J-B Chanson","year":"2013","unstructured":"Chanson J-B, Alame M, Collongues N et al (2013) Evaluation of clinical interest of anti-aquaporin-4 autoantibody follow up in neuromyelitis optica. Clin Dev Immunol 2013:146219","journal-title":"Clin Dev Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10257-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10257-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10257-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T04:45:52Z","timestamp":1635914752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10257-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10257"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10257-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"1 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. Siritho serves as a speaker honoraria from Merck Serono, Pacific Healthcare (Thailand), Menarini (Thailand), Biogen Idec, UCB (Thailand), Eisai Inc, Sanofi-Aventis, Terumo BCT and Novartis. No other disclosures were reported. T. Nopsopon reports no disclosures. K. Pongpirul reports no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}